(Q44049081)

29 November 2017

title

An update on current practices in the management of ocular toxoplasmosis (English)

1 reference

29 November 2017

0 references

Gary N Holland

1

1 reference

29 November 2017

Kevan G Lewis

series ordinal

2

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

American Journal of Ophthalmology

29 November 2017

published in

1 reference

29 November 2017

volume

134

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

102-114

1 reference

Therapy for ocular toxoplasmosis

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Azithromycin for ocular toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

[Treatment of toxoplasmosis retinochoroiditis with atovaquone in an immunocompetent patient]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Atypical, severe toxoplasmic retinochoroiditis in elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Ocular toxoplasmosis after the fifth decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Ocular toxoplasmosis in human immunodeficiency virus-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Eye manifestations of congenital toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Recurrent ocular disease in postnatally acquired toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Intraocular inflammatory reactions without focal necrotizing retinochoroiditis in patients with acquired systemic toxoplasmosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Reconsidering the pathogenesis of ocular toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Serologic evaluation of patients with primary and recurrent ocular toxoplasmosis for evidence of recent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

A follow-up study of Toxoplasma gondii infection in southern Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Ocular toxoplasmosis: new directions for clinical investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Standardization of vitreal inflammatory activity in intermediate and posterior uveitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Trimethoprim-sulfamethoxazole in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Treatment of ocular toxoplasmosis with clindamycin and sulfadiazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Ocular Tissue Absorption of Clindamycin Phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Clindamycin in the treatment of toxoplasmic retinochoroiditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Editorial: Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Fulminant ocular toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

Current practices in the management of ocular toxoplasmosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901526-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9394(02)01526-X

1 reference

29 November 2017

1 reference